Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones
PLOS One · 12.11.2026 · 21 (11) · e0362221
DOI: 10.1371/journal.pone.0362221 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 12.11.2026. Verfasst von Wipawadee Ruengdej und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Science, MSc Program in Research for Enterprise, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Sialic Acid Binding Ig-like Lectin 2, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chulalongkorn University, Ministry of Public Health, National Research Council of Thailand.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, including in many cases of CD19-negative disease. In this study, we generated and characterized novel anti-CD22 monoclonal antibody–derived CAR constructs for in vitro evaluation. Four anti-CD22 monoclonal antibody clones were initially screened, and two clones, 24A7G6 and 29H9C8, were selected for CAR development based on their favorable binding and CAR surface expression profiles. Second-generation CAR constructs containing either a 4−1BB or CD28 costimulatory domain were generated and introduced into primary human T cells. The resulting CAR T cells were evaluated for expansion, immunophenotype, activation and inhibitory marker expression, cytokine secretion, short-term cytotoxicity, long-term co-culture activity, and sequential tumor rechallenge against CD22-positive Raji and Nalm-6 cells and CD22-negative K562 cells. Both 24A7G6- and 29H9C8-derived CAR T cells expanded efficiently, showed predominant CD8 + populations with naïve and central memory phenotypes, and mediated potent antigen-specific cytotoxicity against CD22-positive target cells, while showing no activity against CD22-negative cells. Following antigen stimulation, CAR T cells upregulated activation markers and showed modest increases in inhibitory receptors. In long-term co-culture and sequential rechallenge assays, all constructs retained antitumor activity under prolonged antigen exposure. Notably, the 24A7G6-CD28 CAR demonstrated enhanced sustained tumor control compared with the corresponding 4−1BB construct in extended assays, whereas short-term cytotoxicity was broadly comparable across constructs. These findings show that the newly generated 24A7G6 and 29H9C8 scFvs can function as effective targeting domains for CD22-directed CAR T-cell development and provide an in vitro basis for prioritizing lead constructs for further preclinical evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmaceutical Science, MSc Program in Research for Enterprise, Chulalongkorn University, Bangkok, Thailand.
- Center of Excellence in Cellular Immunotherapy, Chulalongkorn University, Bangkok, Thailand.
- Cell and Gene Therapy Manufacturing Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
- Faculty of Medicine, Center of Excellence in Systems Biology, Chulalongkorn University, Bangkok, Thailand.
- Thailand Hub of Talents in Cancer Immunotherapy, Bangkok, Thailand.
- Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
ORCID-Profile: Vichaya Chuthaphakdikun, Nithidol Sakunrangsit, Supannikar Tawinwung, Koramit Suppipat
Förderung
- Chulalongkorn University
- Ministry of Public Health
- National Research Council of Thailand
Zitieren
APA
Ruengdej, W., Chuthaphakdikun, V., Jewmoung, S., Sakunrangsit, N., Boonkrai, C., Pisitkun, T., Tawinwung, S., & Suppipat, K. (2026). Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones. PLOS One, 21(11), e0362221. https://doi.org/10.1371/journal.pone.0362221
Vancouver
Ruengdej W, Chuthaphakdikun V, Jewmoung S, Sakunrangsit N, Boonkrai C, Pisitkun T, et al. Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones. PLOS One. 2026;21(11):e0362221. doi:10.1371/journal.pone.0362221
BibTeX
@article{Ruengdej2026,
author = {Ruengdej, Wipawadee and Chuthaphakdikun, Vichaya and Jewmoung, Sirirut and Sakunrangsit, Nithidol and Boonkrai, Chatikorn and Pisitkun, Trairak and Tawinwung, Supannikar and Suppipat, Koramit},
title = {Generation and in vitro functional characterization of anti-CD22 chimeric antigen receptor T cells derived from newly generated monoclonal antibody clones},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {11},
pages = {e0362221},
doi = {10.1371/journal.pone.0362221}
}
EUVIMED